Weight Loss Effect of Akkermansia Muciniphila in Obese Patients

Launched by WECARE PROBIOTICS CO., LTD. · Jan 14, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating how a specific type of bacteria, called Akkermansia muciniphila, can help with weight loss in obese patients. The researchers are particularly interested in understanding how this bacteria might improve not only weight but also inflammation and other health markers related to metabolism. Participants will undergo various tests to examine changes in their brain function and gut bacteria before and after taking Akkermansia muciniphila.

To be eligible for this study, participants need to be between 18 and 65 years old and have a body mass index (BMI) between 28 and 35, which classifies them as obese. They must also be willing to follow the study guidelines and complete all required tests. However, certain individuals, such as pregnant or lactating women, those who have taken antibiotics recently, or anyone with serious health conditions, will not be able to participate. If chosen for the trial, participants can expect to learn more about their health and contribute to important research that may help others facing similar weight challenges in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • -
• • 1) Age 18-65 years old; 2）28≤BMI≤35Kg/m2； 3) Willing and able to comply with the protocol during the study period, and be able to cooperate with the completion of various examinations during the trial. Written informed consent is provided prior to entry into study screening, and the patient has understood that the study can be withdrawn at any time from the study without any loss
• Exclusion Criteria:
• • 1. Pregnant or lactating women, in the reproductive period and not taking contraceptive measures;
• • 2. Oral antibiotics in the past 1 month prior to enrollment;
• • 3. No use of probiotic prebiotic products before 3 weeks of intervention;
• • 4. people without a fitness fat loss program or history of gastric surgery during the intervention period;
• • 5. Patients with severe gastrointestinal diseases;
• • 6. Those who are known to be allergic to synbiotics or similar products;
• • 7. Patients with no self-awareness and those with mental abnormalities;
• • 8. Have a history of organ transplantation or malignant tumor disease;
• • 9. Concurrent use of other experimental drugs or in other clinical trials;
• • 10. Have a history of alcohol, tobacco and other drug abuse;
• • 11. Those who are expected to be unable to complete the magnetic resonance examination;
• • 12. Combined with serious medical diseases or conditions: such as clinically serious (i.e., active) cardiac disease, severe, uncontrolled medical diseases and infections, severe uncontrollable digestive disorders, severe electrolyte disorders, active disseminated intravascular coagulation, major organ failure, such as decompensated heart, pulmonary, hepatic, renal failure, peripheral neuropathy symptoms, etc.